The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal ...

The White House has ordered the National Institutes of Health (NIH) to study "regret" among transgender people who have ...

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs ...

The pair examine industry trends, company closures, developments in the cell and gene space—and the reductions in force ...

After more than 13 years at Johnson & Johnson, including most recently serving as new ventures lead for Italy within J&J ...

With its remote endovascular procedure system currently under review at the FDA, Microbot Medical has put forward positive ...

In late March, Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced 10,000 layoffs across ...

“Leadership in the agency’s been decapitated, and I think that was somewhat deliberate,” Janet Woodcock, M.D., former acting ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist ...

Big Pharma-backed Atalanta Therapeutics is ramping up for the clinical debut of the company’s lead epilepsy asset in the wake ...

Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...

Kronos Bio is vacating its corporate headquarters amid a wider cost-cutting exercise for the struggling biotech. | Kronos Bio ...